PYXS · XBRL financial data

Pyxis Oncology financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PYXS's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	16,146	13,858
Cost of revenue	—	—	—	475	2,388
Research and development	51,054	86,129	49,586	58,747	73,696
General and administrative	18,663	37,352	32,610	25,420	22,194
Total operating expenses	69,717	123,481	82,196	—	—
Operating income (loss)	(69,717)	(123,481)	(82,196)	(89,460)	(84,420)
Interest income	23	2,764	1,842	930	650
Income tax expense (benefit)	—	—	—	(2,164)	1,386
Net income (loss)	(75,975)	(120,717)	(73,790)	(77,331)	(79,621)
Earnings per share, basic USD per share	(8.95)	(3.65)	(1.85)	(1.32)	(1.28)
Earnings per share, diluted USD per share	(8.95)	(3.65)	(1.85)	(1.32)	(1.28)
Weighted average shares, basic thousands of shares	8,493	33,033	39,905	58,446	62,143
Weighted average shares, diluted thousands of shares	8,493	33,033	39,905	58,446	62,143

Fiscal years (PYXS's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	274,735	179,293	9,664	19,473	15,422
Marketable securities	—	—	109,634	107,458	51,435
Prepaid and other current assets	2,466	5,847	3,834	4,037	3,776
Total current assets	278,673	186,612	124,604	132,440	72,105
Property and equipment, net	1,007	11,165	11,872	9,899	7,997
Right-of-use asset	232	13,602	12,942	12,242	11,418
Total assets	280,021	211,379	173,726	157,181	91,520
Accounts payable	11,951	7,097	3,896	4,859	10,885
Accrued liabilities	6,592	24,537	12,971	11,371	8,554
Total current liabilities	18,708	31,634	25,759	17,680	21,131
Lease liability, non-current	—	18,921	20,099	18,650	16,958
Total liabilities	18,708	50,555	48,022	36,430	38,112
Accumulated deficit	(91,718)	(212,435)	(286,225)	(363,556)	(443,177)
Total stockholders' equity	261,313	160,824	125,704	120,751	53,408
Total liabilities and equity	280,021	211,379	173,726	157,181	91,520
Common shares outstanding (cover page) thousands of shares	32,842	36,981	58,133	61,590	62,831

Fiscal years (PYXS's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(75,975)	(120,717)	(73,790)	(77,331)	(79,621)
Stock-based compensation	6,441	15,764	16,946	12,945	11,801
Depreciation and amortization	647	709	1,927	2,982	4,511
Net cash from operating activities	(35,326)	(89,335)	(70,709)	(57,672)	(63,502)
Purchases of property and equipment	540	6,399	6,726	237	9
Net cash from investing activities	(590)	(6,399)	(104,849)	8,155	58,857
Net cash from financing activities	304,044	183	5,929	59,326	594
Net change in cash	268,128	(95,551)	(169,629)	9,809	(4,051)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pyxis Oncology	18,855	not reported	(18,206)*	83.4M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	15,594	736	(22,394)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.